-
1
-
-
0842277242
-
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition
-
Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433-8
-
(2004)
Circulation
, vol.109
, Issue.3
, pp. 433-438
-
-
Grundy, S.M.1
Brewer Jr., H.B.2
Cleeman, J.I.3
Smith Jr., S.C.4
Lenfant, C.5
-
2
-
-
0035897696
-
Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
-
Adult Treatment Panel III. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285(19):2486-97
-
(2001)
J Am Med Assoc
, vol.285
, Issue.19
, pp. 2486-2497
-
-
-
3
-
-
0029037649
-
Pathophysiology of insulin resistance in human disease
-
Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75(3):473-86
-
(1995)
Physiol Rev
, vol.75
, Issue.3
, pp. 473-486
-
-
Reaven, G.M.1
-
4
-
-
0027406191
-
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
-
Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434-44
-
(1993)
Diabetes Care
, vol.16
, Issue.2
, pp. 434-444
-
-
Stamler, J.1
Vaccaro, O.2
Neaton, J.D.3
Wentworth, D.4
-
5
-
-
0042665536
-
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
-
Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108(4):414-9
-
(2003)
Circulation
, vol.108
, Issue.4
, pp. 414-419
-
-
Sattar, N.1
Gaw, A.2
Scherbakova, O.3
-
6
-
-
0346962890
-
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
-
Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
-
(2004)
Am J Cardiol
, vol.93
, pp. 136-141
-
-
Girman, C.J.1
Rhodes, T.2
Mercuri, M.3
-
7
-
-
0032560807
-
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
-
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339(4):229-34
-
(1998)
New Engl J Med
, vol.339
, Issue.4
, pp. 229-234
-
-
Haffner, S.M.1
Lehto, S.2
Ronnemaa, T.3
Pyorala, K.4
Laakso, M.5
-
8
-
-
0037678289
-
Management of dyslipidemia in adults with diabetes
-
Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26(Suppl 1):S83-S86
-
(2003)
Diabetes Care
, vol.26
, Issue.SUPPL. 1
-
-
Haffner, S.M.1
-
9
-
-
4344575902
-
European guidelines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)
-
De Backer G, Ambrosioni E, Borch-Johnsen K, J et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(4):S1-S10
-
(2003)
Eur J Cardiovasc Prev Rehabil
, vol.10
, Issue.4
-
-
De Backer, G.1
Ambrosioni, E.2
Borch-Johnsen, K.J.3
-
10
-
-
1242273622
-
Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: Findings in EUROASPIRE II
-
De Backer G. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atheroscler Suppl 2002;2(4):13-6
-
(2002)
Atheroscler Suppl
, vol.2
, Issue.4
, pp. 13-16
-
-
De Backer, G.1
-
11
-
-
0034723758
-
The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
-
Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160(4):459-67
-
(2000)
Arch Intern Med
, vol.160
, Issue.4
, pp. 459-467
-
-
Pearson, T.A.1
Laurora, I.2
Chu, H.3
Kafonek, S.4
-
12
-
-
0001132313
-
Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE 1 and II in nine countries. EUROASPIRE I and II Group. European action on secondary prevention by intervention to reduce events
-
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE 1 and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357(9261):995-1001
-
(2001)
Lancet
, vol.357
, Issue.9261
, pp. 995-1001
-
-
-
13
-
-
0037524291
-
Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events
-
Foley KA, Simpson Jr RJ, Crouse III JR, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92(1):79-81
-
(2003)
Am J Cardiol
, vol.92
, Issue.1
, pp. 79-81
-
-
Foley, K.A.1
Simpson Jr., R.J.2
Crouse III, J.R.3
Weiss, T.W.4
Markson, L.E.5
Alexander, C.M.6
-
14
-
-
0035881018
-
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins
-
Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111 (3):185-91
-
(2001)
Am J Med
, vol.111
, Issue.3
, pp. 185-191
-
-
Andrews, T.C.1
Ballantyne, C.M.2
Hsia, J.A.3
Kramer, J.H.4
-
15
-
-
0032168473
-
Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines
-
Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998;98(9):851-5
-
(1998)
Circulation
, vol.98
, Issue.9
, pp. 851-855
-
-
Frolkis, J.P.1
Zyzanski, S.J.2
Schwartz, J.M.3
Suhan, P.S.4
-
16
-
-
0034776367
-
Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function
-
van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134(2):409-17
-
(2001)
Br J Pharmacol
, vol.134
, Issue.2
, pp. 409-417
-
-
Van Heek, M.1
Farley, C.2
Compton, D.S.3
Hoos, L.4
Davis, H.R.5
-
17
-
-
0034003105
-
Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
-
van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129(8):1748-54
-
(2000)
Br J Pharmacol
, vol.129
, Issue.8
, pp. 1748-1754
-
-
Van Heek, M.1
Farley, C.2
Compton, D.S.3
-
18
-
-
10744221008
-
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption
-
Altmann SW, Davis Jr HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303(5661):1201-4
-
(2004)
Science
, vol.303
, Issue.5661
, pp. 1201-1204
-
-
Altmann, S.W.1
Davis Jr., H.R.2
Zhu, L.J.3
-
19
-
-
0037504445
-
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial
-
Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107(19):2409-15
-
(2003)
Circulation
, vol.107
, Issue.19
, pp. 2409-2415
-
-
Ballantyne, C.M.1
Houri, J.2
Notarbartolo, A.3
-
20
-
-
0037111890
-
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
-
Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90(10):1084-91
-
(2002)
Am J Cardiol
, vol.90
, Issue.10
, pp. 1084-1091
-
-
Gagne, C.1
Bays, H.E.2
Weiss, S.R.3
-
21
-
-
0037441702
-
Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia
-
Kerzner B, Corbelli J, Sharp S, A et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91(4):418-24
-
(2003)
Am J Cardiol
, vol.91
, Issue.4
, pp. 418-424
-
-
Kerzner, B.1
Corbelli, J.2
Sharp, S.A.3
-
22
-
-
0344490262
-
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial
-
Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24(8):717-28
-
(2003)
Eur Heart J
, vol.24
, Issue.8
, pp. 717-728
-
-
Melani, L.1
Mills, R.2
Hassman, D.3
-
23
-
-
0037132598
-
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
-
Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40(12):2125-34
-
(2002)
J Am Coll Cardiol
, vol.40
, Issue.12
, pp. 2125-2134
-
-
Davidson, M.H.1
McGarry, T.2
Bettis, R.3
-
24
-
-
0027243348
-
Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
-
Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 1993;269(23):3015-23
-
(1993)
J Am Med Assoc
, vol.269
, Issue.23
, pp. 3015-3023
-
-
-
25
-
-
0037407197
-
Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease
-
Nishizawa Y, Shoji T, Kakiya R, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2003;(84):S117-S120
-
(2003)
Kidney Int Suppl
, Issue.84
-
-
Nishizawa, Y.1
Shoji, T.2
Kakiya, R.3
-
26
-
-
0032568089
-
Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy
-
Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81(4A): 26B-31B
-
(1998)
Am J Cardiol
, vol.81
, Issue.4 A
-
-
Frost, P.H.1
Havel, R.J.2
-
27
-
-
0029832009
-
Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
-
Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94(3):273-8
-
(1996)
Circulation
, vol.94
, Issue.3
, pp. 273-278
-
-
Lamarche, B.1
Moorjani, S.2
Lupien, P.J.3
-
28
-
-
0242442147
-
Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)
-
Williams K, Sniderman AD, Sattar N, D'Agostino Jr R, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003;108(19):2312-6
-
(2003)
Circulation
, vol.108
, Issue.19
, pp. 2312-2316
-
-
Williams, K.1
Sniderman, A.D.2
Sattar, N.3
D'Agostino Jr., R.4
Wagenknecht, L.E.5
Haffner, S.M.6
-
29
-
-
0031861930
-
Plasma triglyceride as a risk factor for cardiovascular disease
-
Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 1998;14(Suppl B):14B-17B
-
(1998)
Can J Cardiol
, vol.14
, Issue.SUPPL. B
-
-
Austin, M.A.1
-
30
-
-
0346996795
-
Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein
-
Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-8
-
(2003)
Am J Cardiol
, vol.92
, pp. 1414-1418
-
-
Sager, P.T.1
Melani, L.2
Lipka, L.3
-
31
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
-
(2002)
Lancet
, vol.360
, Issue.9326
, pp. 7-22
-
-
|